CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
29.95
+0.59 (2.01%)
At close: Feb 4, 2025, 4:00 PM
31.02
+1.07 (3.57%)
After-hours: Feb 4, 2025, 4:47 PM EST
CG Oncology Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for CG Oncology stock have an average target of 65.11, with a low estimate of 50 and a high estimate of 75. The average target predicts an increase of 117.40% from the current stock price of 29.95.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 7 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 8 | 8 | 8 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +150.42% | Jan 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +150.42% | Jan 10, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Jan 7, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $66 | Buy | Reiterates | $66 | +120.37% | Dec 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +150.42% | Dec 6, 2024 |
Financial Forecast
Revenue This Year
632.40K
from 204.00K
Increased by 210.00%
Revenue Next Year
503.88K
from 632.40K
Decreased by -20.32%
EPS This Year
-1.34
from -15.65
EPS Next Year
-1.85
from -1.34
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.1M | 2.5M | 141.4M | |||
| Avg | 632,400 | 503,880 | 93.0M | |||
| Low | n/a | n/a | 49.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 414.7% | 298.5% | 27,962.2% | |||
| Avg | 210.0% | -20.3% | 18,361.3% | |||
| Low | - | - | 9,624.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.33 | -1.60 | -0.23 |
| Avg | -1.34 | -1.85 | -1.68 |
| Low | -1.37 | -2.09 | -3.03 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.